TScan (NASDAQ: TCRX) loses Amgen Crohn’s collaboration
TScan Therapeutics (TCRX) announced that Amgen has terminated their Research Collaboration and License Agreement for Crohn's disease, effective November 10, 2026. TScan will not face penalties but will lose potential $500M+ in milestones and royalties. The company received a $30M upfront payment in 2023.
How this was made
The 30-second read
Why it matters
The termination removes the collaboration’s future milestone and royalty stream and requires TCRX to wind down current Crohn’s research activities under the agreement’s plan.
Market read
Investors will likely focus on the reduced probability-weighted value of Crohn’s disease milestones and royalties, plus the operational impact of winding down collaboration-driven work.
What to watch
The article does not quantify how much of TCRX’s broader pipeline is tied to Crohn’s, nor does it detail any replacement partnerships or internal funding plans, which could mitigate longer-term valuation impact.
Background
TScan’s Crohn’s collaboration with Amgen used TScan’s target discovery platform to identify T-cell antigens, with upfront and success-based economics.
Ticker impact
TScan Therapeutics says Amgen terminated its Crohn’s Research Collaboration and License Agreement, effective Nov 10, 2026, removing milestone and royalty upside.
Near-term downside bias as investors reprice the loss of potential $500M+ milestones and future royalties tied to the collaboration.
The article discloses a contractual termination with 90 days’ notice, specifies no early termination penalty, and states TCRX does not expect future milestone or royalty payments unless Amgen affiliates continue exploiting candidates.
Market effects
Highlights partner concentration risk in biotech collaborations, especially for platform-to-antigen discovery deals in inflammatory disease.
Limited, primarily affects US-listed biotech sentiment around collaboration-dependent revenue models.
Moderate, as Amgen’s decision signals portfolio reprioritization in Crohn’s disease R&D partnerships.
Counterpoint
TCRX may still retain some upside if Amgen or its affiliates continue exploiting product candidates, meaning the economic impact could be less than the headline $500M+ milestone loss.
Key entities
- companyTScan Therapeutics, Inc.
NASDAQ-listed TCRX, the counterparty whose Crohn’s collaboration with Amgen is being terminated.
- companyAmgen Inc.
The partner exercising its contractual right to terminate the Crohn’s Research Collaboration and License Agreement.
